
4D Molecular Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
4D Molecular Therapeutics is a clinical-stage gene therapy company that engineers adeno-associated virus (AAV) vectors to develop treatments for ophthalmology, cardiology, and pulmonology diseases, including wet age-related macular degeneration and cystic fibrosis.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Kirn DavidSee Remarks | Sell | $750K | 58,061at $12.92 | Oct 5, 2026 |
| Kirn DavidSee Remarks | Sell | $4K | 272at $13.61 | Oct 5, 2026 |
| Bizily ScottChief Legal Officer | Sell | $22K | 1,635at $13.65 | Sep 16, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable FDMT activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.